The cholinergic anti-inflammatory pathway can directly affect skin antibacterial responses via nicotinic acetylcholine receptors (nAChRs). In particular, α7 nAChR (CHRNA7) present in the epidermis modulates the host response to wounding and/or wound bacterial infection. While physiologic inflammation is required to initiate normal wound repair and can be triggered by Toll-like receptor (TLR) activation, chronic inflammation is frequently observed in diabetic wounds and can occur, in part, via excessive TLR2 activation or production. Consequently, this can delay physiologic wound healing responses and increase diabetic host susceptibility to bacterial infection. In this study, we demonstrate that topical nAChR activation diminishes bacterial survival and systemic dissemination in a mouse model of diabetic wound infection, while reducing wound TLR2 production, relative to control mice. We further determined that the antimicrobial peptide activity of diabetic mouse wounds is increased compared to control mice, but this effect is lost following topical nAChR activation. Finally, we observed that human diabetic wounds exhibit impaired α7 nAChR (CHRNA7) abundance and localization relative to human control (nondiabetic) skin. These findings suggest that topical administration of nAChR agonists may improve wound healing and infection outcomes in diabetic wounds by dampening TLR2-mediated inflammation and antimicrobial peptide response, and that the diabetic microenvironment may promote aberrant CHRNA7 production/activation that likely contributes to diabetic wound pathogenesis.
INTRODUCTION
Diabetic wounds diminish the quality of life for millions of patients and pose a significant economic burden on society that exceeds $10B annually in the United States alone. Nearly 15-20% of all patients with diabetes develop lower extremity wounds, and diabetes accounts for >60% of all lower extremity amputations in the United States. [1] [2] [3] Furthermore, bacterial infection is considered a critical component for impaired diabetic wound healing, 4 as a result of compromised leukocyte function, accompanying vascular diseases, inadequate glucose control, and altered host antimicrobial responses. 1 Consequently, research exploring the mechanisms by which stress responses, specifically cholinergic receptors, influence wound healing and infection within the diabetic population is of critical importance from a financial and psychosocial perspective.
In the past several years, research in the areas of neuroendocrine responses related to skin function and infection has expanded considerably. The neuroendocrine system is known to modulate systemic and local immune responses, in part, through the cholinergic pathway, which spans several environments to control inflammation via nicotinic acetylcholine receptors (nAChRs) during stress (i.e., infection, tissue damage, and disease states). With regard to inflammation, the neuronal cholinergic anti-inflammatory pathway was originally found to control inflammation by the α7 nAChR (CHRNA7) on cytokine producing cells during infection and tissue damage through the release of acetylcholine from neuronal tissues. 5 Studies from our laboratory and others using animal and human models have determined that stress and activation of epidermal nAChRs directly influence tissue repair processes and susceptibility to infection through modulation of skin antimicrobial responses. [6] [7] [8] A more recent study also determined that CHRNA7 activation can promote diabetic wound healing by suppressing TNF-α production by glycotoxins, which may be linked with the blockage of NF-κB activation in macrophages, 9 further implicating a role for nAChR activation in diabetic wound healing pathology. Impaired antimicrobial peptide (AMP) activity is one mechanism behind susceptibility to microbial infections and pathologic inflammation, as AMPs stimulate inflammation, provide direct microbicidal activity, and maintain skin barrier integrity. 10 AMP dysregulation can promote the pathogenesis of inflammatory skin diseases and compromises the normal wound healing process in humans. [11] [12] [13] Toll-like receptor 2 (TLR2) is activated after skin wounding or Staphylococcus aureus infection and plays an important role in the induction of AMP production and bacterial clearance, as well as stimulating wound closure. 14, 15 TLR2 recognizes components of Gram-positive bacteria by facilitating heterodimers with TLR1 or TLR6, 16, 17 leading to the recruitment of the intracellular proteins necessary for induction of proinflammatory cytokine and AMP production. 14, 15 Importantly, TLR2 expression, signaling, and functional activation are increased in type 2 diabetes human subjects 18 and experimental skin wounds in diabetic db/db mice. 19 This positive feedback loop leads to excess wound inflammation and delayed wound closure. Furthermore, the cholinergic antiinflammatory pathway was recently implicated in obesityinduced inflammation and insulin resistance, 20 characteristic of diabetic wound patients.
We previously published that keratinocyte nAChR activation dampens TLR2-mediated migration and pro-inflammatory cytokine and AMP production using the TLR2/6 ligand, MALP-2 (macrophage activating lipoprotein-2), which can be restored by a CHRNA7-selective antagonist. We further determined that this response occurred through the NF-κB and Erk1/2 pathways during early and late wound healing. In a mouse model of S. aureus wound infection, topical nAChR activation reduced wound AMP and TLR2 production to augment bacterial survival in wild-type mice, as AMP induction and TLR2 production are known to facilitate bacterial clearance during skin infection. 21 Therefore, we hypothesized that nAChR activation would reduce TLR2 responses in a model of diabetic wound infection to promote healing and reduce bacterial survival, as TLR2 abundance and excess inflammation are believed to impede normal wound healing responses and increase bacterial susceptibility in this model of impaired wound healing. Our findings emphasize the potential benefit of epidermal nAChR activation on aberrant epidermal TLR2-mediated responses to improve diabetic wound healing and infection outcomes and identify a potential defect in epidermal cholinergic responses in diabetic patients.
METHODS

Murine methicillin-resistant S. aureus wound infection model
Mice homozygous for the diabetes spontaneous mutation db (Lepr db/db ) and heterozygous control mice (Lepr db/+ ) (8-10-week-old males) were purchased from Jackson Laboratories (Bar Harbor, ME). All animal experiments were performed with the approval of the Loyola University Chicago, Health Sciences Campus IACUC. Three days prior to treatment start, dorsal mouse fur was plucked under isofluorane anesthesia and immediately depilated. Vehicle (0.1% ethanol in cell-culture tested water) or 10 −9 M nicotine (Sigma) were topically applied to dorsal skin twice a day for 3 days. Subsequently, skin wounds were induced with 3-mm biopsy punches at six sites, and then 10 μL of either vehicle (sterile saline) or the methicillin-resistant S. aureus (MRSA) USA300 strain (10 6 CFU total) was applied topically to each wound. On day 1 postwounding, the mice were humanely euthanized and their wounds and kidneys were excised and prepared for subsequent analyses. To quantify the bacterial burden, one wound and one kidney per mouse was homogenized in sterile Phosphate buffered saline solution (PBS) with 1 mm zirconia beads in a mini bead-beater (BioSpec Products, Bartlesville, OK). The homogenates were serially diluted in PBS and plated on Todd-Hewitt agar plates. After overnight incubation of the agar plates, the bacterial colonies were counted to quantify the colony forming units (CFU/ml) homogenate. The rest of the skin biopsies was immediately frozen after excision on dry ice and stored at −80 C until use.
Enzyme-linked immunosorbent assay
The levels of Interleukin-6 (IL-6), Macrophage inflammatory protein-2 (MIP-2), IL-10, and IL-17A in skin wound homogenates were determined using Enzyme-linked immunosorbent assay (ELISA) kits (PepProTech, Rocky Hill, NJ) according to the manufacturer's protocols.
Western blot
Wounds were pulverized using a liquid nitrogen cooled biopulverizer (Biospec). Powdered tissues were then dissolved in radioimmunoprecipitation assay buffer containing 10 units/mL collagenase (Sigma-Aldrich, St. Louis, MO) and Halt phosphatase and protease inhibitor cocktail (Pierce Biotechnology, Rockford, IL) and incubated for 1 hour at 37 C. Afterwards, the homogenates were sonicated on ice for 10 seconds and then spun at 17,000 x g for 5 minutes. The supernatants were transferred to new tubes and stored at −80 C until use. Protease inhibitor was present in all reagents. The protein samples were heated at 90 C for 5 minutes prior to separation in a 4-20% gradient minigel (Bio Rad, Hercules, CA). Proteins in gels were transferred to poly(vinylidene difluoride) membranes and immunoblotted with the following antibodies at 1:1,000 or 1:2,000 dilution: rabbit polyclonal anti-human β2 microglobulin (Pierce Biotechnology), mouse monoclonal anti-human β-actin (Santa Cruz Biotechnology, Dallas, TX) for cytosolic extracts, mouse monoclonal anti-human TATA box (Millipore, Burlington, MA) for nuclear extracts, rabbit polyclonal anti-TLR2 (Abcam, Cambridge, MA), mouse monoclonal anti-CD14 (Santa Cruz Biotechnology), rabbit polyclonal anti-MyD88 (Cell Signaling, Danvers, MA), antimouse CHRNA7 (Abcam), and mouse monoclonal anti-β-actin at 1:1,000 for cell culture or mouse skin lysates. Goat anti-rabbit HRP or goat anti-mouse HRP (Vector Laboratories, Burlingame, CA) at 1:5,000 were used as secondary antibodies. Visualization of the immunoreactive bands was performed by enhanced chemiluminescence (Pierce Biotechnology). Densitometry of bands was analyzed using ImageJ software (National Institutes of Health, Bethesda, MD). 22 High-pressure liquid chromatography purification of skin extracts Skin samples were placed in 1 N acetic acid for at least 24 hours at 4 C, homogenized, lyophilized, and then dissolved in water. High-pressure liquid chromatography (HPLC) peptide separation was then performed using a C18 column (8 μM, ST 4.6/250; Thermo Scientific, Waltham, MA). Equilibration was done in 0.1% trifluoroacetic acid. Peptides were eluted with an acetonitrile gradient (10-100% over 40 minutes at 2 mL/minute, fractions collected from 10 to 30 minutes). 23 All fractions (2 mL each) were lyophilized and reconstituted in 50 μL of sterile water. The samples were then relyophilized and resuspended in 20 μL sterile water. Samples were then normalized for peptide content.
Antimicrobial radial diffusion assay
Recombined HPLC fractions were evaluated using a radial diffusion assay (RDA), as we described. 6, 21 Antimicrobial activity was assessed against S. aureus (S. aureus ΔmprF). Bacteria were grown overnight in tryptic soy broth (TSB) at 37 C. The overnight cultures were then diluted 1:100, grown to mid-exponential phase, and spectrophotometrically adjusted to the desired CFU concentration in TSB. Agar plates for the RDAs were prepared as previously described. 6 Briefly, 0.5% tryptone medium with 1% SeaKem GTG Agarose (Cambrex Corporation, East Rutherford, NJ) was autoclaved. The agar was cooled to 45 C and the bacteria added to an endconcentration of~4 × 10 5 CFU/mL. Immediately thereafter, 10 mL of the liquid agar with the bacteria was poured into square agar plates. After the agar solidified, the plates were refrigerated to inhibit bacterial growth. Then, 36 holes with defined size were placed into the agar plates by using sterile 1,000-μL pipette tips and vacuum suction. Finally, 2 μL of the skin peptide samples were placed into the holes and the plates incubated for 24 hours at 37 C. Two microliters of sterile water and synthetic catestatin AMP (100 μM, GeneScript, Piscataway, NJ) were used as the negative and positive controls, respectively. The zone of inhibition of bacterial growth (area) was quantified using ImageJ Software. 22 Laser capture microdissection and quantitative polymerase chain reaction Frozen sections mounted onto membrane-slides (Carl Zeiss Microscopy, Thornwood, NY) were fixed in 70% ethanol, and washed with RNase-free distilled water for 5 minutes. Sections were stained with Mayer's hematoxyline, and then rinsed with RNase-free water. After that, dehydration was performed in a quick increasing ethanol series. Laser capture microdissection (LCM) was performed using a PALM Micro Beam System (Zeiss Instruments, Thornwood, NY). Samples from each group were collected and pooled per group into an Adhesive Cap 500 opaque (Carl Zeiss Microscopy) and stored in QIAzol Lysis Reagent (QIAGEN, Germantown, MD) at -80 C. RNA extraction was performed using the miRNeasy Micro Kit (QIAGEN). Complementary DNA was synthesized using iScript cDNA Synthesis Kit (Bio Rad). Quantitative real time reverse transcription polymerase chain reaction (RT-PCR) was performed in triplicate using TaqMan Universal PCR Master Mix (Life Technologies, Carlsbad, CA) on a StepOnePlus Real-Time PCR System (Life Technologies). Fluorogenic probes and primers were used to detect: IL-6 (Mm00446190_m1), MIP-2 (Mm00436450_m1), and TLR2 (Mm00442346_m1) for mouse samples (Life Technologies). Expression of target gene was normalized to β-actin. Expression was analyzed by the 2 -ΔΔCt method.
Immunofluorescence with human diabetic wounds
Discarded tissue was obtained from patients following amputation as a result of diabetic, nonhealing wounds (N = 5; male; white/Hispanic). Amputation procedures included amputation of digits of the lower extremity, transmetatarsal amputation of the foot, below knee amputation, through knee amputation, or above knee amputation. Control skin was collected from tissue discarded following elective surgical procedures (N = 5). Tissue was collected under the IRB protocol 202919 approved by the Loyola Institutional Review Board. A 12 mm 2 area of skin was obtained from an area of active infection without evidence of tissue necrosis. Skin was embedded in OCT. Eight micrometer sections were prepared and subjected to immunofluorescence. To that aim, the sections were washed with wash buffer (Dako, Santa Clara, CA), fixed with 4% paraformaldehyde in PBS, and blocked with protein block solution (3% albumin in Tris buffered saline with Tween). Slides were incubated with mouse monoclonal anti-TLR2 antibody (Chemicon, Temecula, CA) diluted at 1:150 or Rabbit anti-CHRNA7 (R&D, Minneapolis, MN) diluted at 1:200 overnight at 4 C. Mouse IgG (Invitrogen) or rabbit IgG (Abcam) were used as negative controls. Donkey anti-mouse FITC (Millipore) or donkey anti-rabbit antibody Cy3 (Jackson Immuno Research Laboratories) or were used as secondary antibodies. Nuclei were stained using Prolong Antifade Gold with DAPI (Life Technologies). Images were captured with an EVOS FL Digital Microscope (Electron Microscopy Sciences).
Statistical analyses
Values were expressed as means AE SEM. The unpaired t test or unpaired Mann-Whitney test were applied to analyze the differences between two groups. ANOVA with appropriate Sidak's or Bonferroni's posttest were used for multiple comparisons. Analyses were performed using GraphPad Prism for Windows (GraphPad, La Jolla, CA). p-Values smaller than 0.05 were considered to be statistically significant. All statistical analyses were confirmed with Dr. Jim Sinacore, PhD, a biostatistician at Loyola University Chicago.
RESULTS
Topical nicotine reduces bacterial survival and dissemination in diabetic MRSA infected mouse wounds
Bacterial infection, which may eventually systemically spread, is considered a critical component for impaired diabetic wound healing, in part, because of the impaired host antimicrobial responses. 1, 24, 25 Importantly, TLR2 expression, signaling, and functional activation are increased in type 2 diabetes human subjects 26 and diabetic (db/db) mouse wounds. 19 Robust bacterial colonization promotes persistent activation of TLR2 signaling, which can lead to pathologic inflammation. 13, 14, 19, 27 As nAChRs are known to diminish inflammation, we hypothesized that pharmacologic nAChR activation may help reduce the bacterial burden in a diabetic wound model of S. aureus infection. To test this, we subjected control (Lepr
) mice to topical nicotine or vehicle treatment prior to excisional skin wounding and topical MRSA infection, as we previously described. 21 Nicotine treatment increased wound size in day 1 uninfected wounds in diabetic Lepr db/db mice relative to vehicle treatment ( Figure 1A ) but was able to significantly reduce wound size at day 7 postwounding (Figure 1B) . No change in wound size was observed in infected mouse wounds with nicotine treatment in diabetic mice, but it was detrimental for wound healing in control mice ( Figure 1B) . In terms of bacterial survival, control mice treated with nicotine had a significantly increased bacterial burden in wounds 24 hours after MRSA infection ( Figure 1C) . In contrast, nicotine significantly reduced S. aureus MRSA survival in skin wounds ( Figure 1C ) and dissemination into the kidney of Lepr db/db mice ( Figure 1D ).
Topical nicotine normalizes wound AMP activity and reduces pro-inflammatory IL-6 production in MRSAinfected diabetic wounds
Local abundance, as well as peptide charge and hydrophobicity, are important factors that determine effectiveness of a particular AMP, and dictate an AMP's ability to efficiently kill microbes and stimulate later immune responses. 23, 28 To first assess AMP activity and hydrophobic characteristics of wound extracts from control or diabetic wounds subjected to vehicle or nicotine treatment, HPLC was used to fraction wound homogenates prior to analysis of antimicrobial action. Peptides eluted at 10-55% acetonitrile, where AMPs exhibiting greater hydrophobicity eluted from the column at one-minute intervals with increasing percentages of acetonitrile. Fractions from each specimen were subjected to a RDA to assess their capacity to inhibit the growth of an AMP-susceptible mutant, S. aureus ΔmprF. In day 1 uninfected mouse wounds from control or Lepr db/db mice, we did not observe any statistical differences in AMP activity (Figure 2A and C) of wound fractions between uninfected vehicle or nicotine treated mice, as measured by the diameter of bacterial growth inhibition (Figure 2 ). However, we did observe a significant increase in AMP activity in fractions 7 and 14 of MRSA-infected Lepr db/db mice, as well as an increase in peptide hydrophobicity, relative to controls ( Figure 3A and B) . In contrast, topical nicotine treatment normalized AMP activity and hydrophobicity to that of control mice ( Figure 3C and D) .
To next determine if topical nAChR activation would alter AMP-dependent cytokine production, we quantified wound IL-6, IL-17A, TNF-α, and IL-10. We observed a significant reduction in IL-6 in infected diabetic mouse wounds after nicotine treatment, but no change in control wounds ( Figure 4A) . No change was observed in IL-17A, a potent T-cell derived cytokine important for keratinocyte AMP induction, or TNF-α, a pro-inflammatory cytokine negatively regulated by AMPs ( Figure 4B and C) . Although we observed a slight increase in IL-10 in control mouse wounds following nAChR activation, this effect was absent in diabetic mouse wounds ( Figure 4D) . Thus, epidermal nAChR activation appears to dampen aberrant AMP activity and pro-inflammatory IL-6 in MRSA-infected Lepr db/db mice exhibiting known pathologic inflammation and impaired wound healing responses.
Topical nicotine reduces TLR2 and CHRNA7 protein production in MRSA-infected diabetic wounds
We further investigated whether epidermal nAChR activation may be influencing wound antimicrobial and inflammatory responses through changes in TLR2 production in the context of wound infection. Membrane TLR2 (100 kD) protein levels were markedly reduced by~50% in MRSA infected wounds in both control and Lepr db/db mice ( Figure 5A and B). Furthermore, we detected 2 isoforms of the soluble TLR2 receptor (54 and 46 kD) in control mice ( Figure 5A and B). Soluble TLR2 consists mostly of the TLR2 extracellular domain, has been detected in plasma, breast milk, and saliva, 29, 30 and serves as a decoy receptor to prevent overactivation of membrane-bound TLR2. 27, 31 Only the TLR2 membrane and 54 kD soluble form were reduced in infected mouse wounds by nicotine treatment in control mice ( Figure 5A and B) . Intriguingly, Lepr db/db infected mouse wounds were deficient in the 54 kD soluble TLR2, but we did observe a significant reduction in membrane TLR2 by topical nicotine (Figure 5A and B) . No statistical difference in the protein levels of the 46 kD soluble TLR2 was observed in control or Lepr db/db infected mouse wounds ( Figure 5A and B) . Epidermal TLR2 production decreased with topical nicotine in infected wounds from both control and Lepr db/db mice. We further observed that epidermal CHRNA7 production increased with topical nicotine in infected control wounds, but decreased in infected diabetic wounds ( Figure 5A and C) . These results suggest that TLR2 and TLR2-mediated wound healing responses are targeted by epidermal nAChR activation, and that the diabetic microenvironment changes the skin's responsiveness to cholinergic stimuli, and remains to be explored.
To next confirm whether the changes in TLR2 and IL-6 were primarily in the epidermis, laser-capture microdissection was used to isolate RNA from epidermal keratinocytes in mouse wounds (Supporting Information Figure S1 ). Because of the low RNA yield isolated from the epidermis, it was necessary to pool the samples for each group. We determined that TLR2 and IL-6 epidermal gene expression appeared to be more abundant in uninfected diabetic mouse wounds compared to controls, and that topical nAChR activation appeared to reduce epidermal TLR2 and IL-6 more robustly in diabetic wounds than controls, similarly to our protein data in Figure 5 . Future studies are necessary to robustly increase the number of mice to perform statistical analyses, but the data suggest that similar changes in TLR2 and IL-6 occur at both the RNA and protein level, and that these changes likely occur in the epidermis. Of note, we were unable to isolate epidermis from infected diabetic wounds, as these wound sections were not able to be captured by the laser. It was speculated that perhaps epidermal lipid content or another biochemical defect was more abundant in these wounds, rendering them too heavy for the laser capture. However, this concept needs to be further explored in the context of infected diabetic mouse wounds.
CHRNA7 and TLR2 colocalization is altered in human diabetic wounds relative to control skin Finally, we sought to establish proof-of-concept that human chronic wounds exhibited defects in epidermal nAChRs relative to TLR2. As compared to control skin, which exhibited positive staining of CHRNA7 primarily in the stratum corneum, skin from chronic wounds exhibited a more diffuse pattern of CHRNA7 (red) throughout the epidermis (Supporting Information Figure S2 ). TLR2 localization (green) was also more prominent in the dermis in control skin, as compared to chronic wounds, which expressed TLR2 in the more differentiated epidermal layers (Supporting Information Figure S2 ). These results demonstrate a defect in the localization of both CHRNA7 and TLR2 in the epidermis of chronic wounds, which likely influences TLR2-mediated responses involved in diabetic wound pathogenesis.
DISCUSSION
Our results can be simplified in our model of the TLR2/cholinergic axis in the context of cutaneous wound healing (Supporting Information Figure S3 ). TLR2 overactivation, as observed in diabetic subjects and mice, can promote hyper-inflammation and aberrant AMP production, resulting in impaired wound healing. 19, 26, 32 Our previous studies identified a novel mechanism for AMP regulation via the nAChR activation in response to skin infection. 6 Here, we hypothesized that altered states of nAChR activation modulate TLR2 activation, upstream of AMP regulation, to diminish TLR2-dependent wound repair responses. We further hypothesized that this may be beneficial in models of chronic wounds, specifically diabetic wounds, where undesirable TLR2 activation and hyper-inflammation serves to impede wound closure and bacterial resistance. 19, 26, 33 Thus, selective nAChR agonists may have a significant therapeutic potential to improve wound healing in diabetic or other subsets of chronic wounds where infection and/or inflammation is in excess, consequently impeding normal wound healing processes.
Our results confirmed these hypotheses while also revealing that the presence of a TLR2 stimulus (i.e., infection) alters the wound response to nAChR activation. In MRSA infected wounds in control mice, nAChR activation dampens TLR2-mediated pro-inflammatory cytokine and AMP production, which likely contributes to greater bacterial survival and systemic dissemination into the kidney observed in nicotine treated mice. 21 In contrast, topical nicotine reduces bacterial susceptibility in an infected diabetic skin wound along with the reduction of TLR2 production and the presence of alternative isoforms, suggesting that nAChR activation can improve wound healing outcomes in the presence of excess inflammation. We also observed that topical nAChR activation increased wound size in uninfected diabetic mouse wounds at day 1 and infected control wounds at day 7 postwounding. However, wound size was reduced only in uninfected diabetic mouse wounds at day 7 postwounding, indicating a selective nicotine effect in the presence or absence of infection. Alternatively, wound contractability may also account for the differences in lesion size between the mouse strains, which remains to be further explored in subsequent studies.
Excessive inflammation and frequent bacterial colonization are major contributing factors for intractable diabetic foot ulcers. 24 Enhanced TLR2 expression and downstream activation pathways promotes a sustained inflammatory responses and dysfunctional wound healing in the diabetic human and mouse. 19, 26, 32 Consistent with another report,
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TLR2 was increased in migrating and proliferating epidermis in Lepr db/db mouse wounds compared to controls.
Topical nicotine markedly reduced TLR2 production in Lepr db/db mouse wounds, suggesting that nAChR activation may diminish TLR2-mediated responses to improve wound healing responses in diabetic wounds, including the observed normalization of wound AMPs in infected nicotine-treated diabetic mouse wounds. Along these lines, cathelicidin production is reduced in diabetic foot ulcers compared to healthy skin, 34 which likely contributes to greater bacterial susceptibility and delayed wound re-epithelialization. Interestingly, we observed a robust increase in epidermal cathelicidin expression in nicotine-treated Lepr db/db mice compared to vehicle treated or control animals (data not shown). This suggests that something specific about the diabetic phenotype or microenvironment permits a greater responsiveness to topical nAChR activation in terms of cathelicidin regulation, a mechanism that remains to be investigated.
While nicotine increased IL-10 in infected control wounds, this effect was lost in Lepr db/db mice wounds. The nicotine metabolite, cotinine, was previously found to promote an IL-10-dominated anti-inflammatory milieu. 35 IL-17A, which induces AMP expression in keratinocytes, 36 is increased by high glucose treatment in lymphocytes. 37 Consistent with this, we observed greater IL-17A in Lepr db/db mice wounds compared to wild-type wounds (~230%). As diabetic wounds exhibit reduced cathelicidin, 34 increased IL-17A may serve as a compensatory mechanism to increase cathelicidin. Selective nAChR agonists may serve to "normalize" specific cytokines in diabetic wounds to improve the inflammatory microenvironment.
Although topical nicotine application was previously found to accelerate diabetic wound healing by augmenting angiogenesis using nanomolar concentrations, 38 we observed a new mechanism by which nAChR activation dampens TLR2-mediated wound healing responses and influences bacterial survival/dissemination. Our study reveals not only the suppressive effect of nAChR activation on TLR2-mediated wound responses but also new insights and potential drug targets to improve wound healing outcomes in diabetic and other subsets of chronic wounds. The observed increase in TLR2/CHRNA7 colocalization in the epidermis also suggests that their proximity may explain potential paracrine effects by CHRNA7 activation on TLR2 responses, and that the altered distribution of CHRNA7 may be directly contributing to impaired wound healing and antimicrobial responses in diabetic patients, which remains to be further explored.
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Additional supporting information may be found online in the Supporting Information section at the end of the article. ). Migrating and proliferating epidermis of wound were isolated by laser microdissection (n > 4). Samples from each animal were combined for each group, and then qRT-PCR was performed on the pooled samples. Veh, Vehicle; Nic, Nicotine; TLR2, Toll-like receptor 2; IL-6, interleukin-6. Figure S2 . Epidermal TLR2 and CHRNA7 localization is altered in human chronic wounds. Representative immunofluorescence staining for human CHRNA7 (red) and TLR2 (green) in healthy control skin and diabetic wound ulcers visualized as merged image together with DAPI (4 0 ,6-diamidino-2-phenylindole) staining (blue) for cell nuclei. Rabbit IgG or mouse IgG are displayed as negative controls on the right. White dotted lines demarcate epidermal-dermal junction. Scale bars, 200 μm. Figure S3 . Topical nAChR activation dampens TLR2-mediated inflammation in diabetic wounds and improves wound infection outcomes. TLR2/6 agonist induces the formation of the TLR2/TLR6 heterodimerization recruiting CD14, which leads to MyD88 dependent intracellular signaling. nAChR activation in a diabetic wound model characterized by hyper-inflammation appears to be beneficial to control inflammation and reduce bacterial survival. Soluble TLR2 is reduced in diabetic wounds, which can contribute to hyper-inflammation by enhancing TLR2 signaling. nAChR activation improves diabetic wound healing by reducing membrane TLR2 gene expression and protein production, in part, by modulating aberrant pro-inflammatory cytokines and AMP production.
